<table id="table13" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="40%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule" valign="bottom">Concomitant Drug</th>
<th align="center" stylecode="Rrule" valign="bottom">Effect on Concentration of Lamotrigine or Concomitant Drug</th>
<th align="center" stylecode="Rrule" valign="bottom">Clinical Comment</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3">↓ = Decreased (induces lamotrigine glucuronidation).</td>
</tr>
<tr>
<td align="left" colspan="3">↑ = Increased (inhibits lamotrigine glucuronidation).</td>
</tr>
<tr>
<td align="left" colspan="3">? = Conflicting data.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td rowspan="2" stylecode="Botrule Lrule Rrule">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine concentrations approximately 50%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule">↓ levonorgestrel</td>
<td stylecode="Rrule">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Carbamazepine and carbamazepine epoxide</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">? carbamazepine epoxide</td>
<td stylecode="Rrule">May increase carbamazepine epoxide levels.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lopinavir/ritonavir</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine concentration approximately 50%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Atazanavir/ritonavir</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine AUC approximately 32%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenobarbital/Primidone</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifampin</td>
<td stylecode="Rrule">↓ lamotrigine</td>
<td stylecode="Rrule">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Valproate</td>
<td stylecode="Rrule">↑ lamotrigine<br/>
<br/>? valproate</td>
<td stylecode="Rrule">Increased lamotrigine concentrations slightly more than 2-fold. There are conflicting study results regarding effect of lamotrigine on valproate concentrations: 1) a mean 25% decrease in valproate concentrations in healthy volunteers, 2) no change in valproate concentrations in controlled clinical trials in patients with epilepsy.</td>
</tr>
</tbody>
</table>